<DOC>
	<DOCNO>NCT02082639</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety two dos GSK Biologicals ' HPV-16/18 L1 VLP AS04 vaccine co-administered GSK Biologicals ' HAV vaccine accord 0 , 6 month schedule , compare administration either vaccine alone . The study ascertain immune response elicit two vaccine adversely impact compare HPV-16/18 L1 VLP AS04 vaccine HAV vaccine administer alone .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Human Papillomavirus Vaccine ( Cervarix™ ) When Co-administered With GSK Biologicals ' Hepatitis A Vaccine ( Havrix® ) Healthy Female Adolescents Aged 9-14 Years</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A female , include , 9 14 year age time first vaccination . Subjects ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply requirement protocol . Written inform consent obtain parent ( ) /LAR ( ) subject inform assent obtain subject , appropriate , prior enrollment . Healthy subject establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period two month completion vaccination series . Child care . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period ( Month 12 ) . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Inhaled topical steroid allow . Planned administration/administration vaccine foreseen study protocol within period start 30 day 30 day first dose vaccine exception routine vaccine meningococcal , pertussis , inactivate influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day first dose study vaccine . Concurrently participate another clinical study , time study period ( Month 12 ) , subject expose investigational noninvestigational vaccine/product . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period ( Month 12 ) . Previous administration MPL AS04 adjuvant . Previous vaccination hepatitis A planned administration hepatitis A vaccine foreseen study protocol study period ( Month 12 ) . Cancer autoimmune disease treatment . History hepatitis A infection . Known exposure hepatitis A within previous 6 week . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine . Hypersensitivity latex . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screening test , opinion investigator preclude administration study vaccine . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period ( Month 12 ) . Acute disease and/or fever time enrollment . Fever define temperature ≥ 37.0°C oral , axillary tympanic route . The preferred route record temperature study oral axillary .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Adolescents</keyword>
	<keyword>Havrix</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Cervarix</keyword>
	<keyword>Safety</keyword>
</DOC>